Commence Bio Receives 1st Patent for MSC1: A New Cancer Immunotherapy Platform
June 20, 2016 18:45 ET | Commence Bio
SPARKS, MD --(Marketwired - June 20, 2016) - Commence Bio, Inc. (Commence) today announced the issuance of a patent covering the company's STaRT 41™ technology utilized for producing MSC1 cells....
New Potential Lung Cancer Biomarkers Identified
April 19, 2016 08:00 ET | Protea Biosciences, Inc.
NEW ORLEANS, April 19, 2016 (GLOBE NEWSWIRE) -- Protea Biosciences Group, Inc., (OTCQB:PRGB) announced the use of its proprietary bioanalytical technology to achieve the molecular profiling of...
AIMLogo.jpg
Hemispherx's Ampligen(R) Provides Anti-Tumor Activity Analogous to Emerging Immune Checkpoint Inhibitors
December 16, 2014 08:30 ET | AIM ImmunoTech Inc.
PHILADELPHIA, Dec. 16, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today further progress on developing Ampligen® (rintatolimod)...
red.jpg
RedHill Biopharma Acquires Phase II Oncology Drug MESUPRON(R) From WILEX AG
June 30, 2014 06:00 ET | RedHill Biopharma Ltd.
RedHill expands its late clinical-stage gastrointestinal-focused pipeline with MESUPRON®, an oncology drug targeting gastrointestinal and other solid tumor cancers licensed from Wilex...